- Home
- SOPH vs MGTX Comparison
SOPH vs MGTX Comparison
Compare SOPH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- MGTX
- Stock Information
- Founded
- SOPH 2011
- MGTX 2015
- Country
- SOPH Switzerland
- MGTX United States
- Employees
- SOPH N/A
- MGTX N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOPH Health Care
- MGTX Health Care
- Exchange
- SOPH Nasdaq
- MGTX Nasdaq
- Market Cap
- SOPH 231.8M
- MGTX 744.9M
- IPO Year
- SOPH 2021
- MGTX N/A
- Fundamental
- Price
- SOPH $4.30
- MGTX $8.26
- Analyst Decision
- SOPH Strong Buy
- MGTX Strong Buy
- Analyst Count
- SOPH 1
- MGTX 5
- Target Price
- SOPH $7.00
- MGTX $24.60
- AVG Volume (30 Days)
- SOPH 121.2K
- MGTX 535.4K
- Earning Date
- SOPH 11-04-2025
- MGTX 11-13-2025
- Dividend Yield
- SOPH N/A
- MGTX N/A
- EPS Growth
- SOPH N/A
- MGTX N/A
- EPS
- SOPH N/A
- MGTX N/A
- Revenue
- SOPH $73,297,000.00
- MGTX $27,417,000.00
- Revenue This Year
- SOPH $16.60
- MGTX $110.63
- Revenue Next Year
- SOPH $19.09
- MGTX $212.13
- P/E Ratio
- SOPH N/A
- MGTX N/A
- Revenue Growth
- SOPH 13.66
- MGTX 96.83
- 52 Week Low
- SOPH $2.58
- MGTX $4.55
- 52 Week High
- SOPH $5.30
- MGTX $9.73
- Technical
- Relative Strength Index (RSI)
- SOPH 49.45
- MGTX 45.43
- Support Level
- SOPH $4.21
- MGTX $8.00
- Resistance Level
- SOPH $4.70
- MGTX $9.73
- Average True Range (ATR)
- SOPH 0.38
- MGTX 0.72
- MACD
- SOPH -0.05
- MGTX -0.08
- Stochastic Oscillator
- SOPH 27.13
- MGTX 15.43
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.